相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Invasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, It Spores
Martin Hoenigl
CLINICAL INFECTIOUS DISEASES (2021)
COVID-19 associated with pulmonary aspergillosis: A literature review
Chih-Cheng Lai et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2021)
Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment
Quanhathai Kaewpoowat et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
COVID-19 and fungal infections: Etiopathogenesis and therapeutic implications
Mariana Chumbita et al.
REVISTA ESPANOLA DE QUIMIOTERAPIA (2021)
Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction
Tuija Tapaninen et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study
Sara Blanco-Dorado et al.
PHARMACOTHERAPY (2020)
Proposal of a Safe and Effective Study Design for CYP3A-Mediated Drug-Drug Interactions
Brit Silja Rohr et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations
Christoph Zurl et al.
JOURNAL OF FUNGI (2020)
Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance
Misti Ellsworth et al.
JOURNAL OF FUNGI (2020)
Drug-Drug Interaction Between Isavuconazole and Tacrolimus: Is Empiric Dose Adjustment Necessary?
Wesley D. Kufel et al.
JOURNAL OF PHARMACY PRACTICE (2020)
Itraconazole Dosing and Drug Monitoring at a Tertiary Children's Hospital
Ying Hua Leong et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2019)
The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes
Xingxian Luo et al.
XENOBIOTICA (2019)
Drug-drug interaction study of imatinib and voriconazole in vitro and in vivo
Qianmeng Lin et al.
INFECTION AND DRUG RESISTANCE (2019)
Antifungal drugs: What brings the future?
Ruth Van Daele et al.
MEDICAL MYCOLOGY (2019)
Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability
Haiyan Li et al.
CLINICAL DRUG INVESTIGATION (2019)
Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein
Abby C. Shumaker et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Voriconazole hepatotoxicity as a result of steroid withdrawal in a patient with allergic bronchopulmonary aspergillosis
Sara Blanco-Dorado et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis
Zorica Jovic et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
Therapeutic tools for oral candidiasis: Current and new antifungal drugs
Guillermo Quindos et al.
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL (2019)
Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining
Camille Morival et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT
Beata Sienkiewicz et al.
PATHOLOGY & ONCOLOGY RESEARCH (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole
Matthew W. McCarthy et al.
CLINICAL PHARMACOKINETICS (2018)
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
Jeffrey D. Jenks et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
Sibylle C. Mellinghoff et al.
ANNALS OF HEMATOLOGY (2018)
Prediction of the effect of voriconazole on the pharmacokinetics of non-steroidal anti-inflammatory drugs
Na Li et al.
JOURNAL OF CHEMOTHERAPY (2018)
Clinical hepatotoxicity associated with antifungal agents
Ioannis Kyriakidis et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Romuald Bellmann et al.
INFECTION (2017)
Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis
Qin Xiang Ng et al.
JOURNAL OF AFFECTIVE DISORDERS (2017)
The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review
T. -y. Li et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections
Yuanming Xing et al.
BMC INFECTIOUS DISEASES (2017)
Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
Takao Yamazaki et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects
Takao Yamazaki et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects
Takao Yamazaki et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
Robert Townsend et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients
Ryan M. Rivosecchi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
Andreas H. Groll et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
Amit Desai et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450 (CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers
Piergiorgio Cojutti et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2016)
Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP
Vincent J. C. Lempers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Co-administration of St. John's wort and hormonal contraceptives: a systematic review
Erin N. Berry-Bibee et al.
CONTRACEPTION (2016)
Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole
A. Petitcollin et al.
DRUG METABOLISM AND PHARMACOKINETICS (2016)
Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis
Matt Shirley et al.
DRUGS (2016)
Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH
Anne Schmitt-Hoffmann et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2016)
Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature
K. L. Wallace et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2016)
Isavuconazole: a role for the newest broad-spectrum triazole
Monica A. Slavin et al.
LANCET (2016)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens et al.
LANCET (2016)
Role of isavuconazole in the treatment of invasive fungal infections
Dustin T. Wilson et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Isavuconazole: A New Option for the Management of Invasive Fungal Infections
Natasha N. Pettit et al.
ANNALS OF PHARMACOTHERAPY (2015)
Effect of a High-Fat Meal on the Pharmacokinetics of 300-Milligram Posaconazole in a Solid Oral Tablet Formulation
Wendy M. Kersemaekers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring
T. Kim et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2015)
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent
Jeffrey M. Rybak et al.
PHARMACOTHERAPY (2015)
Pharmacokinetics and Safety Study of Posaconazole Intravenous Solution Administered Peripherally to Healthy Subjects
Wendy M. Kersemaekers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat
Gaotong Lin et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2014)
Clinically relevant drug-drug interactions between antiretrovirals and antifungals
Ramya Krishna Vadlapatla et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections
Taotao Wang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Steady-state pharmacokinetics and metabolism of voriconazole in patients
Marcus J. P. Geist et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data
Fumiyoshi Yamashita et al.
PLOS ONE (2013)
Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions
Jamie L. Fleet et al.
BMJ OPEN (2013)
Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension
Gopal Krishna et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Michael J. Dolton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Fatal rhabdomyolysis following voriconazole and simvastatin
Elizabeth Doran et al.
AUSTRALIAN PRESCRIBER (2012)
Voriconazole in clinical practice
Malgorzata Mikulska et al.
JOURNAL OF CHEMOTHERAPY (2012)
Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network
Christopher G. Rowan et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren
Tuija Tapaninen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Current Concepts in Antifungal Pharmacology
Russell E. Lewis
MAYO CLINIC PROCEEDINGS (2011)
Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview
Hans-Peter Lipp
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Yanjun Li et al.
CLINICAL PHARMACOKINETICS (2010)
Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone
Teijo I. Saari et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect
Peter A. Warn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
Roger J. M. Bruggemann et al.
CLINICAL INFECTIOUS DISEASES (2009)
Voriconazole drastically increases exposure to oral oxycodone
Nora M. Hagelberg et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin
Pertti J. Neuvonen et al.
CLINICAL PHARMACOKINETICS (2008)
Effect of voriconazole on the pharmacokinetics of diclofenac
Ville-Veikko Hynninen et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2007)
Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: Importance of interdisciplinary communication to prevent treatment errors with complex medications
Marcus J. P. Geist et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Pertti J. Neuvonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions
A. Dominguez-Gil Hurle et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Potent cytochrome P4502C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
Gerd Mikus et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of S-(+)- and R-(-)-ibuprofen
Ville-Veikko Hynninen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers
A Sansone-Parsons et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects
JY Park et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers
A Schmitt-Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype
Marcus J. P. Geist et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Pharmacokinetic/pharmacodynamic profile of voriconazole
Ursula Theuretzbacher et al.
CLINICAL PHARMACOKINETICS (2006)
Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes
T Niwa et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics
J Rengelshausen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Oral bioavailability of posaconazole in fasted healthy subjects - Comparison between three regimens and basis for clinical dosage recommendations
F Ezzet et al.
CLINICAL PHARMACOKINETICS (2005)
Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures
BJ Komoroski et al.
DRUG METABOLISM AND DISPOSITION (2004)
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study
D Wexler et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Antifungal agents: In vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy
AH Groll et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2004)
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men
R Courtney et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults
R Courtney et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Role of itraconazole metabolites in CYP3A4 inhibition
N Isoherranen et al.
DRUG METABOLISM AND DISPOSITION (2004)
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
XQ Li et al.
DRUG METABOLISM AND DISPOSITION (2004)
Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use
C Martinez et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds
HK Munayyer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia
SG O'Brien et al.
BRITISH JOURNAL OF CANCER (2003)
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults
R Courtney et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter
YP Chen et al.
MOLECULAR PHARMACOLOGY (2003)
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
R Hyland et al.
DRUG METABOLISM AND DISPOSITION (2003)
Voriconazole: A new triazole antifungal agent
LB Johnson et al.
CLINICAL INFECTIOUS DISEASES (2003)
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole
N Wood et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Effect of food on the pharmacokinetics of multiple-dose oral voriconazole
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Voriconazole does not affect the steady-state pharmacokinetics of digoxin
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity
L Zou et al.
LIFE SCIENCES (2002)
Enantiospecific effects of cytochrome P4502C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2
J Kirchheiner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Clinical significance of the cytochrome P4502C19 genetic polymorphism
Z Desta et al.
CLINICAL PHARMACOKINETICS (2002)
Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine
GM Giancarlo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers
P Saha et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2000)
分享论文
